Following the 2026 Nobel Prize announcements, Japanese companies associated with the Prizes in Physiology or Medicine, Physics and Chemistry have attracted attention, making it important to identify the links between the award-winning themes and the companies. The announcement dates were reported as 5 October for Physiology or Medicine, 6 October for Physics, and 7 October for Chemistry.
Following the 2026 Nobel Prize announcements, funds may flow into stocks whose companies have links to research related to the award-winning themes, and related stocks exist among Japanese companies in fields including drug discovery, advanced materials, semiconductors and batteries. The Prizes in Physiology or Medicine, Physics and Chemistry are scheduled to be announced from 5 to 7 October, respectively, and attention may spread beyond companies directly linked to the winning research to companies in the same fields.
When selecting Nobel Prize-related stocks, the article says that 3 factors should be given priority: relevance to the award-winning theme, progress toward commercialization, and the impact on business performance. It states that investors need to check how far the research results can lead to product development and monetization, rather than relying solely on sympathy buying. The strategy of distinguishing short-term catalysts around the announcements from medium- to long-term growth drivers is emphasized.
As specific examples, ラクオリア創薬（4579）is described as a drug discovery company with ties to ghrelin-related research, while 日立製作所（6501）is linked to research into quantum computers using the electron spin of quantum dots. These are introduced as themes connected with the 2024 and 2025 Citation Laureates. 旭化成（3407）is cited as a stock related to materials and components for lithium-ion batteries, with the share-price movement when Yoshino Akira (吉野 彰) received the Chemistry Prize presented as an example.
The article also suggests that the commercialization of advanced materials such as MOFs and the spillover of quantum technologies could extend across a wide range of industries, and that progress in drug discovery and clinical development in the pharmaceutical and biotechnology sectors could lead to medium- to long-term growth opportunities. It emphasizes the importance of distinguishing short-term catalysts from medium- to long-term commercialization so as not to confuse news with corporate value.